Literature DB >> 15042650

Human papillomavirus type specific DNA and RNA persistence--implications for cervical disease progression and monitoring.

Kate S Cuschieri1, M J Whitley, Heather A Cubie.   

Abstract

In 2000, we monitored the course and persistence of human papillomavirus (HPV) infection in 54 women who were HPV positive and free of any cytological disease using HPV-DNA genotyping with a linear array assay (baseline). The impact of HPV infection on development of cervical cytological abnormality (dyskaryosis) was monitored by repeat HPV genotyping and cytological assessment 2 years later. Detection of mRNA transcripts of known HPV oncogenes E6 and E7 using NASBA methodology and specific molecular beacons for five common HPV types was also performed at both time points. A total of 11/54 (20%) women developed dyskaryosis after 2 years with 31/54 and 23/54 women exhibiting transient and persistent infections respectively, as monitored by DNA genotyping. Women who maintained type-specific persistent HPV infection were significantly more likely to develop dyskaryosis compared to those who exhibited a transient infection (P = 0.001). The presence of HPV mRNA E6/E7 transcripts was less sensitive but more specific for the detection of disease at follow up. Moreover, women who were DNA positive and also positive for mRNA transcripts at baseline were significantly more likely to harbour persistent infection compared to those in whom DNA only was detected at baseline (P = 0.013). This study highlights the importance of detecting persistent type specific HPV infection to identify those women more at risk of developing cervical abnormalities, either by repeated DNA genotyping, or potentially by RNA based techniques that may be more predictive of persistent infection if performed at a single time point. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15042650     DOI: 10.1002/jmv.20062

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  29 in total

1.  Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.

Authors:  Samuel Ratnam; Francois Coutlee; Dan Fontaine; James Bentley; Nicholas Escott; Prafull Ghatage; Veeresh Gadag; Glen Holloway; Elias Bartellas; Nick Kum; Christopher Giede; Adrian Lear
Journal:  J Clin Microbiol       Date:  2010-06-23       Impact factor: 5.948

2.  High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush.

Authors:  Antoinette A T P Brink; Chris J L M Meijer; Maarten A H M Wiegerinck; Thedoor E Nieboer; Roy F P M Kruitwagen; Folkert van Kemenade; Nathalie Fransen Daalmeijer; Albertus T Hesselink; Johannes Berkhof; Peter J F Snijders
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

3.  Assessment of MagNA pure LC extraction system for detection of human papillomavirus (HPV) DNA in PreservCyt samples by the Roche AMPLICOR and LINEAR ARRAY HPV tests.

Authors:  Matthew P Stevens; Elice Rudland; Suzanne M Garland; Sepehr N Tabrizi
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

4.  Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology.

Authors:  Andreas Clad; Miriam Reuschenbach; Johanna Weinschenk; Ruth Grote; Janina Rahmsdorf; Nikolaus Freudenberg
Journal:  J Clin Microbiol       Date:  2010-12-29       Impact factor: 5.948

5.  Inhibitory effects of dobutamine on human gastric adenocarcinoma.

Authors:  Hui-Xia Zheng; Li-Na Wu; Hong Xiao; Qian Du; Jian-Fang Liang
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

6.  A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo.

Authors:  S Hovland; M Arbyn; A K Lie; W Ryd; B Borge; E J Berle; H Skomedal; T M Kadima; L Kyembwa; E M Billay; D Mukwege; R B Chirimwami; T M Mvula; P J Snijders; C J L M Meijer; F Karlsen
Journal:  Br J Cancer       Date:  2010-03-02       Impact factor: 7.640

7.  Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test.

Authors:  D C Rijkaart; V M H Coupe; F J van Kemenade; D A M Heideman; A T Hesselink; W Verweij; L Rozendaal; R H Verheijen; P J Snijders; J Berkhof; C J L M Meijer
Journal:  Br J Cancer       Date:  2010-08-31       Impact factor: 7.640

Review 8.  Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis.

Authors:  Anne F Rositch; Jill Koshiol; Michael G Hudgens; Hilda Razzaghi; Danielle M Backes; Jeanne M Pimenta; Eduardo L Franco; Charles Poole; Jennifer S Smith
Journal:  Int J Cancer       Date:  2012-10-11       Impact factor: 7.396

9.  RNA (E6 and E7) assays versus DNA (E6 and E7) assays for risk evaluation for women infected with human papillomavirus.

Authors:  Paola Cattani; Alessia Siddu; Sara D'Onghia; Simona Marchetti; Rosaria Santangelo; Valerio G Vellone; Gian Franco Zannoni; Giovanni Fadda
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948

Review 10.  Gene discovery in cervical cancer : towards diagnostic and therapeutic biomarkers.

Authors:  Cara M Martin; Louise Kehoe; Cathy O Spillane; John J O'Leary
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.